• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重新思考心力衰竭临床试验:心力衰竭协作实验室

Rethinking heart failure clinical trials: the heart failure collaboratory.

作者信息

Alkalbani Mutaz, Psotka Mitchell A

机构信息

Department of Cardiology, Inova Schar Heart and Vascular, Falls Church, VA, United States.

出版信息

Front Cardiovasc Med. 2024 Jan 24;11:1350569. doi: 10.3389/fcvm.2024.1350569. eCollection 2024.

DOI:10.3389/fcvm.2024.1350569
PMID:38327488
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10847294/
Abstract

The Heart Failure Collaboratory (HFC) is a consortium of stakeholders in the heart failure (HF) community that aims to improve the infrastructure of clinical research to promote development of novel therapies for patients. Since its launch in 2018, HFC has implemented several solutions to tackle obstacles in HF clinical research including training programs to increase the number of clinicians skilled in conducting clinical trials, novel study designs, and advocacy for a diverse and inclusive HF research ecosystem. We highlight some of the HFC successes since its establishment.

摘要

心力衰竭协作实验室(HFC)是心力衰竭(HF)领域利益相关者的一个联盟,旨在改善临床研究基础设施,以促进为患者开发新疗法。自2018年成立以来,HFC实施了多项解决方案,以克服HF临床研究中的障碍,包括开展培训项目以增加具备临床试验技能的临床医生数量、采用新颖的研究设计,以及倡导建立一个多元化和包容性的HF研究生态系统。我们重点介绍HFC自成立以来取得的一些成功成果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92a9/10847294/709bb678688f/fcvm-11-1350569-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92a9/10847294/283ba1c6f9e3/fcvm-11-1350569-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92a9/10847294/709bb678688f/fcvm-11-1350569-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92a9/10847294/283ba1c6f9e3/fcvm-11-1350569-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92a9/10847294/709bb678688f/fcvm-11-1350569-g002.jpg

相似文献

1
Rethinking heart failure clinical trials: the heart failure collaboratory.重新思考心力衰竭临床试验:心力衰竭协作实验室
Front Cardiovasc Med. 2024 Jan 24;11:1350569. doi: 10.3389/fcvm.2024.1350569. eCollection 2024.
2
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF.达格列净的疗效评估:心力衰竭协作组医学治疗评分的影响——来自 DAPA-HF 的研究结果。
JACC Heart Fail. 2022 Aug;10(8):543-555. doi: 10.1016/j.jchf.2022.03.009. Epub 2022 Jun 8.
3
Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort.在中国 4880 例队列中,射血分数保留、轻度降低和降低的心衰患者的 5 年死亡率。
ESC Heart Fail. 2022 Aug;9(4):2336-2347. doi: 10.1002/ehf2.13921. Epub 2022 Apr 18.
4
Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction.左心房容积和左心室质量指数在射血分数保留和降低的心力衰竭中的变化。
ESC Heart Fail. 2021 Aug;8(4):2458-2466. doi: 10.1002/ehf2.13366. Epub 2021 Jun 4.
5
Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure.心房颤动与射血分数保留心力衰竭患者心力衰竭进展风险。
ESC Heart Fail. 2022 Oct;9(5):3254-3263. doi: 10.1002/ehf2.14004. Epub 2022 Jul 4.
6
Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST-CHF study.心力衰竭射血分数保留与降低患者的生物标志物谱:DIAST-CHF 研究结果。
ESC Heart Fail. 2023 Feb;10(1):200-210. doi: 10.1002/ehf2.14167. Epub 2022 Oct 2.
7
Myocardial expression of somatotropic axis, adrenergic signalling, and calcium handling genes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction.射血分数保留的心力衰竭和射血分数降低的心力衰竭中生长激素轴、肾上腺素能信号传导及钙处理相关基因的心肌表达
ESC Heart Fail. 2021 Apr;8(2):1681-1686. doi: 10.1002/ehf2.13067. Epub 2021 Jan 29.
8
Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.射血分数降低的心力衰竭的恢复和结局:一项前瞻性研究。
Eur J Heart Fail. 2017 Dec;19(12):1615-1623. doi: 10.1002/ejhf.824. Epub 2017 Apr 6.
9
[Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].[中国实际临床实践中住院心力衰竭患者的当代流行病学与治疗]
Zhonghua Xin Xue Guan Bing Za Zhi. 2019 Nov 24;47(11):865-874. doi: 10.3760/cma.j.issn.0253-3758.2019.11.004.
10
Characteristics and Outcomes of Adult Outpatients With Heart Failure and Improved or Recovered Ejection Fraction.射血分数改善或恢复的成年心力衰竭门诊患者的特征和结局。
JAMA Cardiol. 2016 Aug 1;1(5):510-8. doi: 10.1001/jamacardio.2016.1325.

引用本文的文献

1
Conductive Microfibers Improve Stem Cell-Derived Cardiac Spheroid Maturation.导电微纤维可改善干细胞来源的心脏球体成熟度。
J Biomed Mater Res A. 2025 Jan;113(1):e37856. doi: 10.1002/jbm.a.37856.
2
Embracing innovation and advancing care: integrating learning health system principles into Inova Schar Heart and Vascular.拥抱创新,推进医疗:将学习型健康系统原则融入Inova Schar心脏与血管中心。
Front Cardiovasc Med. 2024 Oct 24;11:1409303. doi: 10.3389/fcvm.2024.1409303. eCollection 2024.

本文引用的文献

1
Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel.功能性和症状性临床终点:HFC-ARC 科学专家小组。
JACC Heart Fail. 2022 Dec;10(12):889-901. doi: 10.1016/j.jchf.2022.09.012. Epub 2022 Nov 9.
2
Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory.提高心力衰竭试验中代表性不足的种族和族裔人群的入组率:心力衰竭协作组的行动呼吁。
JAMA Cardiol. 2022 May 1;7(5):540-548. doi: 10.1001/jamacardio.2022.0161.
3
The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic.
GUIDE-HF 试验:心力衰竭肺动脉压监测对 COVID-19 大流行的影响。
Eur Heart J. 2022 Jul 14;43(27):2603-2618. doi: 10.1093/eurheartj/ehac114.
4
Global burden of heart failure: a comprehensive and updated review of epidemiology.心力衰竭的全球负担:流行病学的全面更新综述
Cardiovasc Res. 2023 Jan 18;118(17):3272-3287. doi: 10.1093/cvr/cvac013.
5
Under-Enrollment of Obese Heart Failure with Preserved Ejection Fraction Patients in Major HFpEF Clinical Trials.射血分数保留的肥胖型心力衰竭患者在主要射血分数保留的心力衰竭临床试验中的入组不足。
J Card Fail. 2022 May;28(5):723-731. doi: 10.1016/j.cardfail.2021.12.007. Epub 2021 Dec 18.
6
Empower the Future… Even Oprah Had a Mentor!赋能未来……就连奥普拉都有一位导师!
JACC Heart Fail. 2021 Aug;9(8):604-605. doi: 10.1016/j.jchf.2021.06.006.
7
Cultivating Interest in Heart Failure Careers: Can We Reverse the Current Trend?: Cultivating Interest in Heart Failure Careers.培养对心力衰竭领域职业的兴趣:我们能否扭转当前趋势?:培养对心力衰竭领域职业的兴趣。
J Card Fail. 2021 Jul;27(7):819-821. doi: 10.1016/j.cardfail.2021.04.009.
8
Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel.COVID-19 时代的临床试验实施:JACC 科学专家小组。
J Am Coll Cardiol. 2020 Nov 17;76(20):2368-2378. doi: 10.1016/j.jacc.2020.09.544.
9
Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation.限制平均生存时间分析在心力衰竭临床试验评估和解释中的应用。
JACC Heart Fail. 2020 Dec;8(12):973-983. doi: 10.1016/j.jchf.2020.07.005. Epub 2020 Oct 7.
10
Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者心血管结局试验中的心力衰竭终点:临床和监管问题的批判性评估。
Circulation. 2019 Dec 17;140(25):2108-2118. doi: 10.1161/CIRCULATIONAHA.119.042155. Epub 2019 Dec 16.